Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1319-0170 | Registry Identifier | ICTRP |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is an observational, longitudinal, non-interventional real-world study in the United States. The study is meant to describe the experience of participants with a history of stage 2 type 1 diabetes who have been infused with teplizumab and the experience of participants with stage 2 type 1 diabetes who have not been infused with teplizumab, and to compare descriptively the experiences of the two groups.
Primary Objective:
- To characterize health related quality of life, diabetes-related anxiety, diabetes-related burden, and ease of diabetes management, and how participants feel, form and function in those who infused and those who did not infuse with teplizumab
Secondary Objectives:
Each participant is expected to participate in the study from the time of their enrollment through the last data delivery, which is estimated to occur five years after the first participant is enrolled.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with a history of teplizumab infusion | Participants with a history of stage 2 type 1 diabetes who have been infused with teplizumab at the time of enrollment |
| |
| Participants with no history of teplizumab infusion | Participants with stage 2 type 1 diabetes who have not been infused with teplizumab at the time of enrollment |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Teplizumab | Drug | This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in participant and caregiver-reported outcomes from survey responses: ease of diabetes management questions | From baseline, repeated every 6 months up to end of study, approximately 5 years | |
| Change in participant and caregiver-reported outcomes from survey responses: Psychological well-being World Health Organization-5 (WHO-5) | From baseline, repeated every 6 months up to end of study, approximately 5 years | |
| Change in participant and caregiver-reported outcomes from survey responses: State-Trait Anxiety Inventory (STAI) | From baseline, repeated every 6 months up to end of study, approximately 5 years | |
| Change in participant and caregiver-reported outcomes from survey responses: Type 1 Diabetes Distress Assessment System-Core Scale (T1-DDAS CORE) | From baseline, repeated every 6 months, up to end of study, approximately 5 years | |
| Change in participant and caregiver-reported outcomes from survey responses: Diabetes constraints scale | From baseline, repeated every 6 months up to end of study, approximately 5 years | |
| Sociodemographic screening characteristics | At enrollment | |
| Sociodemographic medical history characteristics | At enrollment | |
| Sociodemographic diabetes management characteristics | At enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in characteristics of participants: monitoring practices (e.g. continuous glucose monitor, self-monitoring blood glucose, blood drawn by clinician) across type 1 diabetes stages | From enrollment up to study end, approximately 5 years | |
| Changes in characteristics of participants: medical history across type 1 diabetes stages |
Not provided
Inclusion Criteria:
Exclusion Criteria:
- Failure to complete the baseline survey
Not provided
Not provided
Not provided
Individuals with a history of Stage 2 T1D (documented in medical records) and infused with teplizumab or not infused with teplizumab
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Trial Transparency email recommended (Toll free for US & Canada) | Contact | 800-633-1610 | option 6 | Contact-US@sanofi.com |
| PicnicHealth For potential study participants | Contact | 415-680-3085 | hello@picnichealth.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Investigational Site | Recruiting | San Francisco | California | 94107 | United States |
Not provided
| Label | URL |
|---|---|
| OBS18679 Tepli-QUEST website for potential participants | View source |
Not provided
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| From enrollment up to study end, approximately 5 years |
| Time from index date to the diagnosis of stage 3 type 1 diabetes | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: HbA1c | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: blood glucose | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: post prandial glucose | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: c-peptide | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: time in range in participants with glucose monitor data | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: time above range in participants with glucose monitor data | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: time below range in participants with glucose monitor data | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: glucose variability percent in participants with glucose monitor data | From baseline up to end of study, approximately 5 years |
| Changes in glucose parameters: percent coefficient of variation in participants with glucose monitor data | From baseline up to end of study, approximately 5 years |
| Changes in glucose paremeters: glucose management indicator in participants with glucose monitor data | From baseline up to end of study, approximately 5 years |
| Number of complications (including micro- and macrovascular occurrences and hypoglycemia occurrences) | From baseline up to end of study, approximately 5 years |
| The frequency of glycemic vs. autoantibody testing related to stage 2 type 1 diabetes diagnosis | At enrollment |
| The sequence (first or second) of glycemic testing vs. autoantibody testing related to stage 2 type 1 diabetes diagnosis | Sequence describes if glycemic testing or autoantibody testing took place first in stage 2 type 1 diabetes diagnosis | At enrollment |
| The frequency of misclassification with type 2 diabetes | At enrollment |
| The time between misclassification with type 2 diabetes and autoantibody testing | At enrollment |
| The time between misclassification with type 2 diabetes and the correct diagnosis of stage 2 type 1 diabetes | At enrollment |
| Time from index date to the diagnosis of stage 3 type 1 diabetes for those misclassified with type 2 diabetes where diagnosis is confirmed by HbA1c and/or glycemic measures | From baseline up to end of study, approximately 5 years |
| Proportion (%) of participants using home glycemic monitoring assessments (Continuous Glucose Monitor, self-monitoring blood glucose, urine glucose monitoring) vs in-clinic assessments (HbA1c, fasting blood glucose, c-peptide) | From baseline up to end of study, approximately 5 years |
| Proportion (%) of participants using insulin characterized by insulin dosing, type, regimen, and mode of administration | From baseline up to end of study, approximately 5 years |
| Annualized rate of hospitalizations due to type 1 diabetes complications | From baseline up to end of study, approximately 5 years |
| Annualized rate of emergency room visits due to type 1 diabetes complications | From baseline up to end of study, approximately 5 years |
| Annualized rate of specialist (including endocrinologist) visits | From baseline up to end of study, approximately 5 years |
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C502540 | teplizumab |
Not provided
Not provided
Not provided